1stOncology™: Cancer Intelligence Service – Page 27 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

On September 22, 2026 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, reported it will host a virtual key opinion leader (KOL) event on Monday, October 5, 2026 at 8:00 AM ET featuring Oladapo Yeku, M.D., Ph.D., FACP (Harvard Medical School, Massachusetts General Hospital), who will join company management to discuss COM701 and the evolving treatment landscape in ovarian cancer. To register, click here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Dr. Yeku will preview the randomized MAIA-ovarian adaptive platform trial design of COM701, a potential first-in-class anti-PVRIG antibody, evaluating safety and efficacy in the maintenance treatment of relapsed platinum sensitive ovarian cancer (PSOC), with median progression-free survival data from the interim analysis expected by Q1 2027.

Compugen’s Research and Discovery team will also provide an update on expanded capabilities of Unigen, its AI/ML-powered target discovery platform, which enables the discovery of novel cancer immunotherapy drug targets and the continuous advancement of the next generation of immuno-oncology innovation.

A live question and answer session will follow the formal presentations.

About Oladapo Yeku, MD, PhD, FACP

Dr. Oladapo Yeku is an Associate Professor of Medicine at Harvard Medical School and the Director of Translational Research for the Gynecologic Oncology Program at Massachusetts General Hospital. He is a Vice Chair of the Mass General Brigham Institutional Review Board and an Associate Editor at NEJM Evidence. Dr. Yeku completed his Medical Oncology fellowship training at Memorial Sloan Kettering Cancer Center (MSKCC) and is an expert on immunotherapy for gynecologic cancers. Dr. Yeku is actively involved as a Principal Investigator in early-phase drug development and adoptive cellular therapy clinical trials. His laboratory studies the immunosuppressive tumor microenvironment in Gynecologic Cancers and develops immunotherapeutic approaches such as Antibody Drug Conjugates (ADC), Bispecific T-cell Engagers, and Chimeric Antigen Receptor (CAR) T-cells to overcome these obstacles.

About COM701

COM701 is Compugen’s potential first-in-class anti-PVRIG antibody, a novel immune checkpoint identified through Compugen’s computational discovery platform. COM701 has been evaluated in Phase 1 clinical studies as monotherapy and in combination, with data demonstrating initial signs of anti-tumor activity and a favorable safety and tolerability profile. COM701 is currently being evaluated in the randomized MAIA-ovarian adaptive platform trial as a maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer.

(Press release, Compugen, SEP 22, 2026, View Source;Unigen-Platform-Update-on-October-5-2026/default.aspx [SID1234670995])

IN8bio to Present at Sidoti Small-Cap Virtual Conference

On September 22, 2026 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, reported that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026.

Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company presentation on Thursday, September 24. The presentation will provide an overview of IN8bio’s differentiated γδ T cell platform and pipeline, including its lead T cell engager program, INB-619, and clinical-stage programs in oncology.

Sidoti Small-Cap Virtual Conference
Date: Thursday, September 24, 2026
Time: 1:00 p.m. ET
Presenter: William Ho, Chief Executive Officer and Co-Founder
Webcast: View Source

A live webcast of the presentation will be available through the Investors section of IN8bio’s website. A replay will be available following the event.

(Press release, In8bio, SEP 22, 2026, View Source [SID1234670994])

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

On September 22, 2026 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, reported that an abstract featuring updated interim results from the ongoing Phase 1 ACESOT-1051 study of its WEE1 inhibitor APR-1051 in patients with advanced solid tumors has been accepted for oral presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain.

"We look forward to presenting an update from our ongoing Phase 1 ACESOT-1051 trial at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium and sharing these data with the international oncology community," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "This meeting brings together leading investigators, clinicians and researchers focused on advancing new approaches in cancer treatment, and we welcome the opportunity to discuss our program with the broader oncology community in Barcelona."

Presentation Details:

Title: Interim results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)
Presenting Author: Timothy A. Yap, MBBS, PhD, FRCP
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and Investigator in the ACESOT-1051 study
Session: Plenary Session (Oral Presentation)
Date and Time: Friday, November 20, 2026, 3:00 PM – 3:10 PM CET
Location: Room 111 + 112, CCIB, Barcelona.

For more information on the ACESOT-1051 trial, refer to ClinicalTrials.gov NCT06260514.

(Press release, Aprea, SEP 22, 2026, View Source [SID1234670993])

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

On September 22, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported to have issued a letter to stockholders from Chief Executive Officer Thomas Equels addressing the recent U.S. Food and Drug Administration (the "FDA") approval of daraxonrasib and outlining the Company’s view of Ampligen’s differentiated mechanism, clinical profile and potential role in the future treatment of pancreatic cancer.

The full letter follows:

Dear Fellow Stockholders,

The FDA’s recent approval of daraxonrasib is meaningful progress for people with metastatic pancreatic cancer. In fact, it is significant enough that you may be asking – and I should answer – two questions:

Question 1: How is AIM’s drug Ampligen different from daraxonrasib?

Daraxonrasib is a selective, targeted therapy that inhibits RAS, a major driver of pancreatic cancer. A pivotal, randomized, well-controlled study demonstrated median overall survival of 13.2 months with daraxonrasib compared to 6.7 months with standard chemotherapy, for an improvement of 6.5 months (See Figure 1 below, NEJM). These results are an important part of the basis for the FDA’s approval of daraxonrasib, but they also indicate that many patients on both daraxonrasib and on standard therapy experience disease progression and mortality. Further, in laboratory studies, pancreatic tumors have been seen to develop resistance to RAS inhibition.

Ampligen has a different mechanism of action from daraxonrasib. We believe that Ampligen is the only clinically advanced investigational TLR3 agonist with a well-developed safety profile that is designed to activate innate immunity and help therapeutically reshape the tumor microenvironment to provide a natural mechanism to eliminate cancer cells. While daraxonrasib directly inhibits one driver mutation related to pancreatic cancer, Ampligen has the potential to induce a broad-spectrum therapeutic effect that amplifies a patient’s innate immune system, with data suggesting the potential for consequent stabilization of the pancreatic cancer tumor immune responses with improvement in a patient’s Quality of Life. We have seen evidence of this therapeutic potential not only in pancreatic cancer, but in a range of other solid tumors.

Question 2: What role will Ampligen serve in the future of pancreatic cancer care?

Daraxonrasib is an important therapeutic advance, but pancreatic cancer is not a simple disease where one successful targeted drug makes additional therapeutic development unnecessary. We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have historically limited treatment success in pancreatic cancer.

Further, we believe that Ampligen has significant potential in pancreatic cancer as a monotherapy. In an analysis of patients with a blood neutrophil-to-lymphocyte ratio below 4.5 who participated in a Dutch government-approved Named Patient Program, Ampligen as a monotherapy was linked to a median overall survival of 34.8 months compared with only 12.5 months in well-matched historical controls, representing an observed increase in median overall survival of 22.3 months over the historical controls.

The accompanying chart visually summarizes the respective overall-survival results cited in this letter, including the separate control and treatment comparisons for daraxonrasib and Ampligen based on the separate cited datasets.

In conclusion, daraxonrasib’s approval does not preclude a potentially important role for Ampligen. Daraxonrasib targets a single driver of pancreatic cancer, while Ampligen is designed to work by activating and enhancing the body’s innate immune system to target multiple types of solid tumors, including cancers of the pancreas. Based on all that we know to date, we believe that Ampligen continues to have an important potential role to serve in pancreatic cancer treatment.

AIM is also invested in Ampligen’s potential as a part of a combination therapy with checkpoint inhibitors in a broad range of other solid tumors, including pancreatic cancer. The ongoing Phase 2 DURIPANC clinical trial is evaluating Ampligen with AstraZeneca’s durvalumab (Imfinzi) in patients whose pancreatic cancer was stable post-FOLFIRINOX. This is an exploratory, open-label, single-center study with a small number of patients. Its primary endpoint is the proportion of patients who have stable disease or a tumor response 24 weeks after combination treatment begins. We anticipate topline results from the DURIPANC study in Q1 2027, followed by a detailed analysis of overall survival in Q3 2027. AIM believes that Ampligen’s observed immune activity will translate into a meaningful clinical signal and allow us to establish the parameters of a follow-up, pivotal Phase 3 clinical trial.

While there is still work to be done, including rigorous pivotal trials, our goal remains clear: to determine whether Ampligen can contribute to longer and better lives for patients with pancreatic cancer. We believe it can.

(Press release, AIM ImmunoTech, SEP 22, 2026, View Source [SID1234670992])

Overview of PDS biotech drug development programs (Oncology)

On September 22, 2026 PDS biotech presented its corporate presentation.

(Presentation, PDS Biotechnology, SEP 22, 2026, View Source [SID1234670991])